Similarly, administration of the proteasome inhibitor, bortezomib, resulted in immunogenic cell death in lymphoma and myeloma xenografts in mice through CRT redistribution and upregulation of heat shock proteins (HSP70/90), facilitating DC maturation and activation [35,36,37,38]. This evidence concerns the gene CALR and lymphoma.